Filana Therapeutics, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-91.0M | $-24.3M | $-97.2M | $-76.2M | $-32.4M | $-6.3M | $-4.6M | $-6.6M |
| Depreciation & Amortization | — | — | — | — | — | $22.0K | $58.0K | $69.0K |
| Depreciation | $903.0K | $952.0K | $1.1M | $804.0K | $310.0K | $22.0K | — | — |
| Amortization | $33.0K | $180.0K | $446.0K | $497.0K | $224.0K | $0 | — | — |
| Stock-Based Compensation | $19.6M | $16.3M | $4.6M | $2.1M | $1.8M | $988.0K | $1.3M | $2.4M |
| Net Cash from Operating Activities | $-32.3M | $-116.9M | $-82.0M | $-77.5M | $-30.2M | $-5.4M | $-2.5M | $-4.8M |
| Investing Activities | ||||||||
| Capital Expenditures | $581.0K | $103.0K | $414.0K | $2.7M | $22.2M | — | $18.0K | — |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-581.0K | $-103.0K | $-414.0K | $-2.7M | $-22.2M | $360.0K | $-18.0K | — |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $-239.0K | $124.5M | $2.6M | $47.8M | $192.3M | $75.4M | $5.8M | $14.1M |
| Net Change in Cash | — | — | — | — | — | — | — | $9.3M |
| Free Cash Flow | $-32.8M | $-117.0M | $-82.4M | $-80.2M | $-52.4M | — | $-2.5M | — |